# A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

> **NCT07189325** · PHASE3 · NOT_YET_RECRUITING · sponsor: **University Hospital, Montpellier** · enrollment: 250 (estimated)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis (RRMS)
- Anti-CD20 Therapy

## Interventions

- **DRUG:** Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons)
- **DRUG:** Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)

## Key facts

- **NCT ID:** NCT07189325
- **Lead sponsor:** University Hospital, Montpellier
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2030-09
- **Final completion:** 2030-09
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07189325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07189325, "A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT07189325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*